- Home
- DTIL vs ALGS Comparison
DTIL vs ALGS Comparison
Compare DTIL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | ALGS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 49.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTIL | ALGS |
|---|---|---|
| Price | $4.37 | $6.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $60.00 | $46.67 |
| AVG Volume (30 Days) | ★ 152.6K | 39.2K |
| Earning Date | 03-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | $3,611,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.53 | $3.76 |
| 52 Week High | $8.82 | $14.52 |
Technical Indicators
Market Signals| Indicator | DTIL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 43.01 |
| Support Level | $4.17 | $6.18 |
| Resistance Level | $4.61 | $8.84 |
| Average True Range (ATR) | 0.26 | 0.57 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 79.89 | 42.48 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.